These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35656636)

  • 21. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
    Corrigan PA; Beaulieu C; Patel RB; Lowe DK
    Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
    Carr MJ; Sun J; DePalo D; Rothermel LD; Song Y; Straker RJ; Baecher K; Louie RJ; Stahlie EHA; Wright GP; Naqvi SMH; Kim Y; Sarnaik AA; Karakousis GC; Lowe MC; Delman KA; van Akkooi ACJ; Ollila DW; Collichio F; Zager JS
    Ann Surg Oncol; 2022 Feb; 29(2):791-801. PubMed ID: 34648098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma.
    Fazel M; AlRawashdh N; Alamer A; Curiel-Lewandrowski C; Abraham I
    Expert Opin Biol Ther; 2021 Dec; 21(12):1647-1653. PubMed ID: 34693839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
    Andtbacka RH; Ross M; Puzanov I; Milhem M; Collichio F; Delman KA; Amatruda T; Zager JS; Cranmer L; Hsueh E; Chen L; Shilkrut M; Kaufman HL
    Ann Surg Oncol; 2016 Dec; 23(13):4169-4177. PubMed ID: 27342831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective.
    Franke V; Stahlie EHA; van der Hiel B; van de Wiel BA; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    J Immunother; 2022 Jul-Aug 01; 45(6):263-266. PubMed ID: 35580326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
    Ressler JM; Karasek M; Koch L; Silmbrod R; Mangana J; Latifyan S; Aedo-Lopez V; Kehrer H; Weihsengruber F; Koelblinger P; Posch C; Kofler J; Michielin O; Richtig E; Hafner C; Hoeller C
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.
    Dummer R; Gyorki DE; Hyngstrom J; Berger AC; Conry R; Demidov L; Sharma A; Treichel SA; Radcliffe H; Gorski KS; Anderson A; Chan E; Faries M; Ross MI
    Nat Med; 2021 Oct; 27(10):1789-1796. PubMed ID: 34608333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
    Harrington KJ; Andtbacka RH; Collichio F; Downey G; Chen L; Szabo Z; Kaufman HL
    Onco Targets Ther; 2016; 9():7081-7093. PubMed ID: 27895500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
    Barker CA; D'Angelo SP; Wasilewski G; Steckler AM; Lian M; Zhang Z; Chapman PB; Shoushtari AN; Ariyan CE
    Radiother Oncol; 2024 Nov; 200():110478. PubMed ID: 39159678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
    Harrington KJ; Kong A; Mach N; Chesney JA; Fernandez BC; Rischin D; Cohen EEW; Radcliffe HS; Gumuscu B; Cheng J; Snyder W; Siu LL
    Clin Cancer Res; 2020 Oct; 26(19):5153-5161. PubMed ID: 32669371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).
    Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
    Garnock-Jones KP
    BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intratumoral administration of CD1c (BDCA-1)
    Schwarze JK; Tijtgat J; Awada G; Cras L; Vasaturo A; Bagnall C; Forsyth R; Dufait I; Tuyaerts S; Van Riet I; Neyns B
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and Histological Response to Talimogene Laherparepvec Therapy in Advanced Melanoma: Impact on Overall Survival.
    Ologun GO; Jones CP; Landrum KR; Pham PV; Ismail S; Long PK; Sorah JD; Stitzenberg KB; Meyers MO; Ollila DW
    J Am Coll Surg; 2024 Apr; 238(4):508-516. PubMed ID: 38224076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
    Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Talimogene laherparepvec monotherapy for head and neck melanoma patients.
    Franke V; Stahlie EHA; Klop WMC; Zuur CL; Berger DMS; van der Hiel B; van de Wiel BA; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Melanoma Res; 2023 Feb; 33(1):66-70. PubMed ID: 36454284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC).
    Mulder EEAP; Stahlie EHA; Verver D; Lemstra C; Been LB; Mooyaart AL; Brabander T; Vegt E; Verburg FA; van der Veldt AAM; Verhoef C; van Akkooi ACJ; Grünhagen DJ
    J Surg Oncol; 2021 Dec; 124(7):1161-1165. PubMed ID: 34235758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.
    Hecht JR; Raman SS; Chan A; Kalinsky K; Baurain JF; Jimenez MM; Garcia MM; Berger MD; Lauer UM; Khattak A; Carrato A; Zhang Y; Liu K; Cha E; Keegan A; Bhatta S; Strassburg CP; Roohullah A
    ESMO Open; 2023 Apr; 8(2):100884. PubMed ID: 36863095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
    Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
    Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.